Malignant neoplasm of kidney
|
0.400 |
Biomarker
|
disease |
BEFREE |
MPA also synergies with IL-2 in clinical treatment of renal cancer.
|
29453736 |
2019 |
Malignant neoplasm of kidney
|
0.400 |
Biomarker
|
disease |
BEFREE |
Is still there a role for IL-2 for solid tumors other than melanoma or renal cancer?
|
28000528 |
2017 |
Malignant neoplasm of kidney
|
0.400 |
Biomarker
|
disease |
BEFREE |
IL2 has been approved by the FDA for the treatment of patients with malignant renal cell cancer and metastatic malignant melanoma.
|
25736261 |
2015 |
Malignant neoplasm of kidney
|
0.400 |
Biomarker
|
disease |
BEFREE |
The administration of IL-2 can lead to durable, complete, and apparently curative regressions in patients with metastatic melanoma and renal cancer.
|
24907378 |
2014 |
Malignant neoplasm of kidney
|
0.400 |
Biomarker
|
disease |
BEFREE |
Despite increasing use of "targeted therapy," interleukin-2 (IL-2) is unique, because this cytokine can induce long-term remissions in 5% to 7% of patients with metastatic melanoma and renal cancer.
|
21577143 |
2011 |
Malignant neoplasm of kidney
|
0.400 |
Biomarker
|
disease |
BEFREE |
Patients with renal cancer and requiring first-line treatment for metastatic disease were randomized 1:1 to receive MVA-5T4 (TroVax(®)) or placebo alongside Sunitinib, IL-2 or IFN-α in a multicentre phase III trial.
|
21387109 |
2011 |
Malignant neoplasm of kidney
|
0.400 |
Therapeutic
|
disease |
CTD_human |
EGFR mutation in kidney carcinoma confers sensitivity to gefitinib treatment: a case report.
|
18625569 |
2009 |
Malignant neoplasm of kidney
|
0.400 |
Therapeutic
|
disease |
CTD_human |
High-dose intensity pulse interleukin-2 with famotidine in metastatic kidney cancer.
|
19409039 |
2009 |
Malignant neoplasm of kidney
|
0.400 |
Therapeutic
|
disease |
CTD_human |
We have treated 14 patients with either metastatic melanoma or kidney cancer, using CY 350 mg/M(2) intravenously (i.v.) over 1 hour followed by a continuous infusion IL-2 9 MIU/M(2)/24 hours for 72 hours and famotidine 20 mg i.v. twice per day.
|
18298334 |
2008 |
Malignant neoplasm of kidney
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We provided novel structural and functional information on the expression of the IL-2 receptor in kidney cancer cells and in other normal and neoplastic human epithelial tissues.
|
17571248 |
2007 |
Malignant neoplasm of kidney
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here, we studied the impact of IL-2 administration on the frequency and function of human CD4+ CD25(hi) T cells in immune intact patients with melanoma or renal cancer.
|
16304057 |
2006 |
Malignant neoplasm of kidney
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Activity of continuous infusion plus pulse interleukin-2 with famotidine in patients with metastatic kidney cancer or melanoma previously treated with interleukin-2.
|
17105418 |
2006 |
Malignant neoplasm of kidney
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer.
|
15897568 |
2005 |
Malignant neoplasm of kidney
|
0.400 |
Biomarker
|
disease |
BEFREE |
A consecutive series of 409 patients with either metastatic melanoma or renal cancer who were treated with high-dose bolus IL-2 in the Surgery Branch, National Cancer Institute, between September 1985 and November 1996 have been analyzed with a median potential follow-up of 7.1 years.
|
9742914 |
1998 |
Malignant neoplasm of kidney
|
0.400 |
Biomarker
|
disease |
BEFREE |
Interleukin-2 and/or IFN-alpha gene therapy may be an effective strategy for treatment of patients with advanced renal cancer.
|
7521786 |
1994 |
Malignant neoplasm of kidney
|
0.400 |
Biomarker
|
disease |
BEFREE |
Depending on the cell line and the vector construct used, lymphokine gene-modified human RC cell lines released 4 to 29 units/10(6) cells of IL-2, or up to 10 units/10(6) cells of IFN-gamma within 48 h. Fluorescence-activated cell sorter analysis of SK-RC-29 cells releasing IFN-gamma showed increased expression of major histocompatibility complex class I antigen, beta 2-microglobulin, and ICAM-1, as well as induction of major histocompatibility complex class II antigen expression [human leukocyte antigen(HLA)-DR, -DP], but no changes in these cell surface markers were observed with SK-RC-29 cells releasing IL-2.
|
1423266 |
1992 |
Malignant neoplasm of kidney
|
0.400 |
Biomarker
|
disease |
BEFREE |
We here describe the isolation, characterization, profile of lymphokine expression and T-cell-receptor gene rearrangement pattern of 444P.3, a CD3+ CD4+ CD8- 4B4+ interleukin-2 (IL-2)-dependent clone derived from the malignant ascites of a patient with renal cell cancer.
|
1968360 |
1990 |